TABLE 3.

Therapy Response Assessment at W12 According to PCWG3 Conventional Imaging, Biochemical (PSA), and EAU/EANM PSMA PET/CT Response Criteria

Unique patient designation	Conventional Imaging	PSA	PSMA PET/CT
7	NE0	Non-PD	NEnt
11	NE0	Non-PD	Non-PD
14	NE0	Non-PD	Non-PD
6	NE0	Non-PD	Non-PD
5	NEnm	Non-PD	Non-PD
18	NEnm	Non-PD	Non-PD
19	NEnm	Non-PD	NEnt
1	Non-PD*	Non-PD	PD
4	Non-PD*	Non-PD	Non-PD
9	Non-PD*	Non-PD	PD
15	Non-PD*	Non-PD	Non-PD
16	Non-PD*	PD	PD
2	Non-PD†	Non-PD	Non-PD
17	Non-PD†	Non-PD	Non-PD
20	Non-PD†	Non-PD	Non-PD
12	PD*	Non-PD	PD
13	PD*	Non-PD	PD
21	PD†	Non-PD	Non-PD

^*Patient for whom response assessment was BS driven.

^†Patient with measurable lesions according to RECIST v1.1.

NE₀ = not evaluable, if no metastases were detected since baseline; NE_nt = not evaluable, if lesions were visible but not evaluable by PSMA imaging; NE_nm = not evaluable, if no measurable lesions were visible on CT and without bone lesions on BS.